November 6, 2020 – Thermo Fisher Scientific Inc. (Waltham, MA) and Innoforce, a bioinnovation-enabling company, have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing.
The new state-of-the-art Good Manufacturing Practices (GMP) facility will become part of Thermo Fisher’s extensive global pharma services network, which includes leading capabilities for drug product development, biologics manufacturing, sterile fill-finish, clinical trials packaging and logistics.
The Hangzhou site will also incorporate stringent quality control processes that meet or exceed regulatory guidelines established by the China National Medical Products Administration (NMPA), the U.S. FDA and appropriate EMEA authorities, Thermo Fisher said.
The new facility is expected to be completed in 2022.